As of June 21, 2025, Sourcebio International PLC (SBI.L) reports a EV/EBITDA of 2.58.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Sourcebio International PLC's EV/EBITDA to Peers
To better understand Sourcebio International PLC's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Sourcebio International PLC (SBI.L) | 2.58 |
| Polski Bank Komorek Macierzystych SA (BKM.WA) | 58.20 |
| Nova Leap Health Corp (NLH.V) | 17.05 |
| Medica Group PLC (MGP.L) | 15.86 |
| GHP Specialty Care AB (GHP.ST) | 12.67 |
| PharmChem Inc (PCHM) | 12.33 |
Compared to its competitors, Sourcebio International PLC's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.